FDA Approval: Frontline Ceritinib for ALK+ NSCLC

preview_player
Показать описание
Mark A. Socinski, MD, reviews the FDA approval of ceritinib in the frontline setting for the treatment of ALK-positive non–small cell lung cancer.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
FDA Approval: Frontline 0:05:31

FDA Approval: Frontline Ceritinib for ALK+ NSCLC

Dr. West on 0:00:55

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

Progression in ALK+ 0:06:51

Progression in ALK+ NSCLC After Frontline Therapy

DEBATE: ALK positive 0:11:38

DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib

Dr. Subbiah on 0:01:07

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

Ceritinib and Other 0:02:00

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

Dr. Liu on 0:01:22

Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC

Second-Line Brigatinib for 0:09:33

Second-Line Brigatinib for ALK/ROS1-Rearranged NSCLC

Dr. Weber on 0:00:59

Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

Segment 2: Molecular 0:26:57

Segment 2: Molecular Targets in NSCLC

Dr. Neal Debates 0:01:27

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC

ASCEND-1 and ASCEND-2: 0:01:23

ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases

Upfront Therapy for 0:04:43

Upfront Therapy for ALK/ROS1-Rearranged NSCLC

Proactive management of 0:03:48

Proactive management of ceritinib-related gastrointestinal reactions – Video abstract 96471

Dose escalation results 0:02:43

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Approval of Alunbrig 0:03:44

Approval of Alunbrig Offers Another Option for ALK Positive NSCLC, But Further Research Is Needed

Dr. Chow on 0:01:48

Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the Brain

ASCEND-4: Upfront Ceritinib 0:06:37

ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

Ceritinib in Crizotinib-Resistant 0:07:21

Ceritinib in Crizotinib-Resistant NSCLC

Treatment of Newly 0:04:37

Treatment of Newly Diagnosed ALK-Rearranged NSCLC

Clinical Trial Design 0:24:38

Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era

ALK+ NSCLC Treatment 0:07:49

ALK+ NSCLC Treatment Options - 2022 Program: Targeted Therapies Forum

IASLC-WCLC 2021 Clinical 0:31:11

IASLC-WCLC 2021 Clinical Panel

ALK Inhibitors for 0:03:44

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib